Abstract: The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.

Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.

Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.

Abstract: The present invention relates to IFN-? fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-? protein. The IFN-? fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-? fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-? fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.

Abstract: The present invention relates to IFN-? fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-? protein. The IFN-? fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-? fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-? fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.

Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.